These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24131029)

  • 1. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.
    Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM
    J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
    Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
    J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
    Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z
    Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
    Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
    Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer.
    Wang B; Wang SW; Zhou Y; Wang SP; Gao Y; Liu HM; Ji SK; Wang SQ; Zheng YC; Zhang C; Mardinoglu A; Liu HM; Chen XB; Dai XJ
    J Med Chem; 2024 Sep; 67(18):16165-16184. PubMed ID: 39264726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
    Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.
    Li Y; Sun Y; Zhou Y; Li X; Zhang H; Zhang G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):207-217. PubMed ID: 33307878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
    Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
    Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
    Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
    Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-Heterocyclic carboxylic ester derivatives of gliotoxin lead to LSD1 inhibitors in gastric cancer cells.
    Shan L; Li Z; Chen H; Ge M; Sun Y; Sun Y; Li Y; Li H; Fu L; Liu H
    Bioorg Chem; 2023 Feb; 131():106150. PubMed ID: 36508940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1.
    Wang B; Zhao B; Pang LP; Zhao YD; Guo Q; Wang JW; Zheng YC; Zhang XH; Liu Y; Liu GY; Guo WG; Wang C; Li ZH; Mao XJ; Yu B; Ma LY; Liu HM
    Pharmacol Res; 2017 Aug; 122():66-77. PubMed ID: 28571892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazole-dithiocarbamate-urea hybrids.
    Duan YC; Zheng YC; Li XC; Wang MM; Ye XW; Guan YY; Liu GZ; Zheng JX; Liu HM
    Eur J Med Chem; 2013 Jun; 64():99-110. PubMed ID: 23644193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents.
    Duan YC; Ma YC; Zhang E; Shi XJ; Wang MM; Ye XW; Liu HM
    Eur J Med Chem; 2013 Apr; 62():11-9. PubMed ID: 23353743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.